The use of ABVD chemotherapy for Hodgkin lymphoma has been endorsed as a mainline treatment with “excellent prognosis and manageable toxicity” in a new Australian retrospective study. The multi-centre study looked at 189 patients with previously untreated HL receiving ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) induction, between November 1999 and December 2014. Authors of the study, ...
Hodgkin lymphoma treatment gets the local nod
3 Mar 2016